Ai

Our proprietary ADMET predictor “ADMET-AI”

AI-ML Drug Discovery Platform

At Greenstone Biosciences, we have built an end-to-end AI-driven drug discovery pipeline that integrates our proprietary iPSC-based multi-omics data with state-of-the-art computational modeling.

Key Capabilities:

  • Target Prioritization: AI models trained on multi-omics datasets from our iPSC biobank identify novel therapeutic targets.
  • Virtual Screening: High-throughput docking using AutoDock Vina and BOLTZ2 across major libraries such as ApexBio and ZINC to find optimal small-molecule binders.
  • Drug Property Prediction: In-house ADMET-AI platform (Swanson et al., Bioinformatics) delivers one of the fastest, most accurate ADMET predictors — available at admet.ai.greenstonebio.com.
  • Cardiotoxicity Modeling: ADMET-AI DICT (Mukherjee et al., Circulation, 2025) predicts drug-induced cardiotoxicity using FDA-labeled datasets (> 1,000 drugs).
  • Organ-Specific Models: Custom predictors for liver, lung, and hematologic toxicity extend safety profiling.
  • Molecular Dynamics: Candidate refinement via OpenMM and Gromacs simulations ensures high-affinity, stable target binding before synthesis.

Why it matters:
Our platform unites AI, biobank data, and molecular simulation to accelerate discovery, reduce attrition, and prioritize safer, more effective therapies.

Databases

Reactome — curated biological pathways
https://reactome.org/

RFdiffusion — generative protein modeling https://github.com/RosettaCommons/RFdiffusion